Eculizumab.
CJ Parker, S Kar, P Kirkpatrick - Nature Reviews Drug Discovery, 2007 - nature.com
CJ Parker, S Kar, P Kirkpatrick
Nature Reviews Drug Discovery, 2007•nature.comAbstract Eculizumab (Soliris; Alexion), a monoclonal antibody that binds to the terminal
complement protein C5, was approved by the FDA for the treatment of patients with
paroxysmal nocturnal haemoglobinuria in March 2007. It is the first therapy to be approved
specifically for the treatment of this rare blood disorder.
complement protein C5, was approved by the FDA for the treatment of patients with
paroxysmal nocturnal haemoglobinuria in March 2007. It is the first therapy to be approved
specifically for the treatment of this rare blood disorder.
Abstract
Eculizumab (Soliris; Alexion), a monoclonal antibody that binds to the terminal complement protein C5, was approved by the FDA for the treatment of patients with paroxysmal nocturnal haemoglobinuria in March 2007. It is the first therapy to be approved specifically for the treatment of this rare blood disorder.
nature.com